← All trials
NCT03642626
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 18, 2018
- Primary completion
- Feb 9, 2024
- Completion date
- Jun 1, 2028
- First posted
- Aug 22, 2018
- Last posted
- Apr 2, 2025
- Enrollment
- 144
- Arms / groups
- 7 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of MinnesotaLead sponsor
- University of MinnesotaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.